Bausch Health
Prezzo: 5.06Società e modello di business
Bausch Health (BHC.US) operates in the healthcare sector, focusing on developing, manufacturing, and marketing a range of pharmaceutical and medical device products. Its core offerings include eye health products, dermatology treatments, and gastrointestinal therapies. The company generates revenue primarily through prescription pharmaceuticals and over-the-counter products, with significant contributions from its eye care segment.
Profilo di investimento
The investment profile of Bausch Health is more aligned with value investors, given its current stock price and financial performance. The company has faced challenges, including declining revenue and negative earnings per share, indicating potential risks. Investors may find it suitable for a medium to long-term horizon, with a focus on recovery rather than immediate growth.
Metriche fondamentali (sperimentale)
- EPS (TTM) — utile per azione degli ultimi 12 mesi, $
- -3.21 Rischio
- Ricavi QoQ — crescita dei ricavi trimestre su trimestre
- -12.3% ↓
- Sorpresa EPS
- -3.7% in linea
- Volatilità 20g
- 2.5% stabile
Traccia in portafoglio
Grafico prezzo
| Data | Prima | Dopo | Motivo |
|---|---|---|---|
| 2026-05-08 15:23 | — | Vendi | Weak fundamentals and negative momentum raise significant concerns. |
| 2026-05-08 05:37 | Vendi | Vendi | Компания демонстрирует отрицательные показатели EPS и снижение выручки, что указывает на ухудшение финансового состояния. Долгосрочные тренды также негативные, что увеличивает риски для инвесторов. |
| 2026-04-25 02:56 | Mantieni | Vendi | Компания показывает смешанные результаты, с недавним ростом на 9.96% за 20 дней, но с общей негативной динамикой на более длительных интервалах. Рекомендуется удерживать акции до ясности в финансовых показателях и страте |
| Data | Analista | Action | Target | Prezzo allora |
|---|---|---|---|---|
| 2026-01-07 12:19 | Truist Financial | Target alzato | 7 → 8 | 7.63 |
| 2025-12-08 21:25 | Barclays | Aggiorna | — → 8 | 6.82 |
Ancora nulla